The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression - Trial NCT06320418
Access comprehensive clinical trial information for NCT06320418 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Recruitment Completed. The study focuses on Ovarian Cancer. Target enrollment is 56 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Ain Shams University
Timeline & Enrollment
N/A
Jun 15, 2022
Jun 01, 2024
Primary Outcome
Association of piR-823 expression with ovarian cancer progression
Summary
Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors,
 attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate.
 Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star
 molecule in epigenetics research. Extensive cellular regulatory functions and aberrant
 expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of
 piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed
 as a potential novel mechanism for OC precision, a step toward ncRNA-precision
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06320418
Non-Device Trial